Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Partnership Established to Probe the Inner Workings of Colon Cancer

By BiotechDaily International staff writers
Posted on 01 Jul 2013
Image: Eearly stage colon cancer using GE’s cancer mapping technology (Photo courtesy of GE).
Image: Eearly stage colon cancer using GE’s cancer mapping technology (Photo courtesy of GE).
New cancer mapping technology has been designed to provide a more detailed study of cancer cells and may provide better clues into how colon cancer develops, progresses, and how it can be curbed.

Vanderbilt University (Nashville, TN, USA) is collaborating with GE Global Research (Niskayuna, NY, USA), the technology development arm for the General Electric Co. (Fairfield, CT, USA), to better define, at the cellular level, how colon tumors form and develop.

Supported by a five-year, USD 3.75 million grant from the Office of the Director of the National Institutes of Health (NIH; Bethesda, MD, USA), the research will evaluate GE’s innovative cancer mapping technology, an automated platform that can probe and analyze up to 60 different disease markers, including proteins and messenger RNAs, in a single tissue sample. The capability to examine dozens of markers at one time provides a more complete outlook of the actual mechanisms of cancer. Currently, a diagnosis of cancer and the choice of which therapy to prescribe are based on the histology of the tumor, and in some cases, the expression of just one or two disease markers inside a patient’s tumor.

The GE-Vanderbilt project, led by GE scientists Michael Gerdes, PhD and Kashan Shaikh, PhD, and Robert Coffey, MD, a professor of cancer research at Vanderbilt, will examine how intestinal stem cells of the colon contribute to tumor formation and progression, and the signaling pathways associated with the disease.

“With GE’s cancer mapping technology, we’re enabling cancer to be viewed in ways it couldn’t previously be seen such as with the activation of different signaling pathways in specific cells,” said Prof. Gerdes, lead scientist at GE Global Research. “With unprecedented views, we hope will come unprecedented insights that tell us more about how cancer forms, how it progresses, and most importantly, how to defeat it.”

GE scientists have developed cutting-edge technology that allows a single tissue section from a sample that is removed during surgery, to be imaged for biosignatures including expression of dozens of proteins and nucleic acids (RNA and DNA) without destroying the integrity of the sample. “As we have learned, no two patient’s cancer is exactly the same. With colon cancer, some patients exhibit a more aggressive form of the disease compared to other patients,” said John Burczak, advanced technology leader in molecular imaging at GE Global Research. “We want to understand these subtleties, so that one day therapies can even be specifically tailored for each patient.”

Dr. Gerdes added that the goal is to identify “the mechanisms that drive the aggressive nature of the cancer, and the role that cancer stem cells play in therapeutic resistance.”

A major problem in cancer diagnosis is the limited amount of molecular data that is available about a specific cancer. With little information, it is difficult to determine more specific characteristics of cancer that could reveal how fast or gradually it may be growing. New breakthroughs in molecular diagnostics are beginning to change this pattern.

GE’s cancer mapping technology will be tested with investigators at Vanderbilt from the Epithelial Biology Center that Prof. Coffey directs. The Coffey lab recently reported the discovery of a new population of relatively quiescent (inactive) intestinal stem cells. These cells express a protein called Lrig1 that acts as a tumor suppressor. This discovery has “given us an entrée to develop some very robust models of colon cancer,” Prof. Coffey said.

GE Global Research is the hub of technology development for all of GE’s businesses. The company has locations in Niskayuna, NY, USA; San Ramon, CA, USA; Bangalore, India; Shanghai, China; Munich, Germany; and Rio de Janeiro, Brazil.

Related Links:

Vanderbilt University
GE Global Research



BIOSIGMA S.R.L.
RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.